Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Tanya Siddiqi, MD, Paul Frankel, PhD, Chris Ruel, MS, Robert W Chen, MD, Kevin R. Kelly, MD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, MD PhD, Edward Newman, PhD

Blood (2014) 124 (21): 4483.

https://doi.org/10.1182/blood.V124.21.4483.4483

Published: 2014

Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD

Blood (2014) 124 (21): 1744.

https://doi.org/10.1182/blood.V124.21.1744.1744

Published: 2014

Journal Articles

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Stefanie A. Hartsink-Segers, C. Michel Zwaan, Carla Exalto, Mirjam W.J. Luijendijk, Valerie S. Calvert, Emanuel F. Petricoin, PhD, William E. Evans, PharmD, Dirk Reinhardt, MD, Válerie de Haas, Maj Hedtjärn, Bo R. Hansen, PhD, Troels Koch, PhD, Huib N. Caron, Rob Pieters, MD, PhD, Monique L. Den Boer, PhD

Blood (2012) 120 (21): 1465.

https://doi.org/10.1182/blood.V120.21.1465.1465

Published: 2012

Journal Articles

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

Ya-Ping Chen, Hui-Ju Lin, Kung-Chao Chang, Jiann-Shiuh Chen, Ming-Ying Tsai, Liang-Yi Hung, Tsai-Yun Chen

Blood (2012) 120 (21): 4907.

https://doi.org/10.1182/blood.V120.21.4907.4907

Published: 2012

Journal Articles

Bortezomib Is Effective for Down Regulation of Gene Transcriptions Specifically Expressed in Clonogenic Myeloma Side Population Cells

Miho Nara, MD, Hiroyuki Tagawa, MD, PhD, Kazuaki Teshima, MD, Atsushi Watanabe, MD, PhD, Mitsugu Ito, MD, Atsushi Kitabayashi, MD, PhD, Masaaki Kume, MD, PhD, Yoshiaki Hatano, MD, PhD, Shinsuke Iida, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2012) 120 (21): 3939.

https://doi.org/10.1182/blood.V120.21.3939.3939

Published: 2012

Journal Articles

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Anupam Verma, MD, J. Kimble Frazer, MD, PhD, Alesia Trakhimets, William Heaton, Jared Bearrs, Steven Warner, PhD, David Bearrs, PhD, Sunil Sharma, MD

Blood (2011) 118 (21): 1519.

https://doi.org/10.1182/blood.V118.21.1519.1519

Published: 2011

Journal Articles

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Paolo Lunghi, PhD, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Manuela Abeltino, Davide Arienti, Anna Maria Cantoni, Attilio Corradi, Antonio Bonati, MD

Blood (2011) 118 (21): 1846.

https://doi.org/10.1182/blood.V118.21.1846.1846

Published: 2011

Journal Articles

Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic Cells

Kalindi Parmar, Ph.D, Patrizia Vinciguerra, Ph.D., Susana Godinho, Ph.D., Abigail Hamilton, BA, David Pellman, MD, Alan D. D'Andrea, MD

Blood (2010) 116 (21): 878.

https://doi.org/10.1182/blood.V116.21.878.878

Published: 2010

Journal Articles

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2 nd and 3 rd Tyrosine Kinase Inhibitors (TKIs)

Liunan Li, MD, Hagop Kantarjian, MD, Meng Zhao, MD, Susan O'Brien, MD, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Elizabeth Burton, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 1238.

https://doi.org/10.1182/blood.V116.21.1238.1238

Published: 2010

Journal Articles

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

Paolo Lunghi, PhD, Laura Mazzera, Manuela Abeltino, Nicola Giuliani, Antonio Bonati, MD

Blood (2010) 116 (21): 4059.

https://doi.org/10.1182/blood.V116.21.4059.4059

Published: 2010

Journal Articles

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Wanlong Ma, Chen-Hsiung Yeh, Tai-Sung Lee, Susan O'Brien, Francis Giles, MD, Zeev Estrov, MD, Jorge Cortes-Franco, MD, Maher Albitar, MD

Blood (2009) 114 (22): 2179.

https://doi.org/10.1182/blood.V114.22.2179.2179

Published: 2009

Journal Articles

Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.

Paolo Lunghi, Laura Mazzera, Antonio Costanzo, Nicola Giuliani, Vittorio Rizzoli, Massimo Levrero, Antonio Bonati

Blood (2009) 114 (22): 1837.

https://doi.org/10.1182/blood.V114.22.1837.1837

Published: 2009

Journal Articles

Innovative Phase I Study of Concomitant and Consecutive Treatment with Dasatinib and MK-0457 in Refractory Ph+ CML and ALL Patients.

Giovanni Martinelli, MD, Cristina Papayannidis, Ilaria Iacobucci, Simona Soverini, PhD, Stefania Paolini, Sandra Santucci, Francesco De Rosa, Daniela Cilloni, MD, Francesca Messa, Fabrizio Pane, MD, Vittorio Meneghini, Panagiota Giannoulia, Emanuela Ottaviani, Nicoletta Testoni, Barbara Lama, Michele Baccarani

Blood (2009) 114 (22): 4277.

https://doi.org/10.1182/blood.V114.22.4277.4277

Published: 2009

Journal Articles

Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.

Leo Kretzner, Anna Scuto, Kowolik Claudia, Richard Jove, Stephen J Forman, MD, Yun Yen, MD, PhD, Mark Kirschbaum, MD

Blood (2009) 114 (22): 1690.

https://doi.org/10.1182/blood.V114.22.1690.1690

Published: 2009

Journal Articles

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

Blood (2009) 113 (18): 4331–4340.

https://doi.org/10.1182/blood-2008-09-178350

Published: 2009

Includes: Supplemental data

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, Gautam Borthakur, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William G. Wierda, Elizabeth M Burton, Jorge Cortes

Blood (2008) 112 (11): 2111.

https://doi.org/10.1182/blood.V112.11.2111.2111

Published: 2008

Journal Articles

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

Franck E Nicolini, MD, PhD, Giovanni Martinelli, Dong-Wook Kim, MD, PhD, Andreas Hochhaus, MD, Michael J. Mauro, MD, Jorge Cortes, MD, Charles Chuah, MBChB, MRCP, MD, Inge Dufva, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Fumiharu Yagasaki, MD, Jay Pearson, PhD, Senaka Peter, MBA, Cesar Sanz Rodriguez, MD, Frank Giles, MD, John M Goldman, DM, FCRP, FRCPath, Wei Zhou, PhD

Blood (2008) 112 (11): 188.

https://doi.org/10.1182/blood.V112.11.188.188

Published: 2008

Journal Articles

Beyond the Gatekeeper: Imatinib- and Dasatinib-Resistant BCR-ABL/F317 Mutations Confer Cross-Resistance to VX-680 but Are Sensitive to a Structural Derivative of VX-680

Corynn Kasap, BS, Nicholas Hertz, B.S., Debora Makino, Ph.D., Kevan Shokat, Ph.D., John Kuriyan, Ph.D., Neil P. Shah, MD, PhD

Blood (2008) 112 (11): 725.

https://doi.org/10.1182/blood.V112.11.725.725

Published: 2008

Journal Articles

Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs

Leo Kretzner, Anna Scuto, Richard Jove, Stephen J. Forman, MD, Yun Yen, MD, PhD, Mark Kirschbaum, MD

Blood (2008) 112 (11): 3628.

https://doi.org/10.1182/blood.V112.11.3628.3628

Published: 2008

Journal Articles

The Analysis of HDAC Inhibitor, Vorinostat Efficacy against Wild Type and BCR-ABL Mutant Positive Leukemia Cells in Monotherapy and in Combination with a Pan-Aurora Kinase Inhibitor, MK-0457

Seiichi Okabe, MD, PhD, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki

Blood (2008) 112 (11): 5025.

https://doi.org/10.1182/blood.V112.11.5025.5025

Published: 2008

NARROW

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Targeting Aurora Kinases in Acute Lymphoblastic Leukemia

Bortezomib Is Effective for Down Regulation of Gene Transcriptions Specifically Expressed in Clonogenic Myeloma Side Population Cells

A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic Cells

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2 nd and 3 rd Tyrosine Kinase Inhibitors (TKIs)

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.

Innovative Phase I Study of Concomitant and Consecutive Treatment with Dasatinib and MK-0457 in Refractory Ph+ CML and ALL Patients.

Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

Beyond the Gatekeeper: Imatinib- and Dasatinib-Resistant BCR-ABL/F317 Mutations Confer Cross-Resistance to VX-680 but Are Sensitive to a Structural Derivative of VX-680

Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs

The Analysis of HDAC Inhibitor, Vorinostat Efficacy against Wild Type and BCR-ABL Mutant Positive Leukemia Cells in Monotherapy and in Combination with a Pan-Aurora Kinase Inhibitor, MK-0457

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only